|
102
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
p<0.03
|
Tissue
|
16322291
|
|
103
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.004
|
Tissue
|
16322291
|
|
104
|
Methylation status of APC
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.004
|
Tissue
|
16322291
|
|
105
|
Methylation status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
P = 0.01
|
Tissue
|
16322291
|
|
106
|
Methylation status of Cyclin D2 + APC
|
mRNA
|
Humans
|
Hypermethylated in Patients who relapsed
|
Prognostic
|
Time to Progression
|
0.01
|
Tissue
|
16322291
|
|
263
|
Methylation Status of NKX2-5
|
mRNA
|
Humans
|
Hypermethylated (2.7% normal vs 14% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
264
|
Methylation Status of CALSTN1
|
mRNA
|
Humans
|
Hypermethylated (2.5% normal vs 12.1% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
265
|
Methylation Status of SPOCK2
|
mRNA
|
Humans
|
Hypermethylated (7.5% normal vs 15.2% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
266
|
Methylation Status of NSE1
|
mRNA
|
Humans
|
Hypermethylated (10.3% normal vs 20.5% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
267
|
Methylation Status of SLC16A12
|
mRNA
|
Humans
|
Hypermethylated (9% normal vs 22% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
268
|
Methylation Status of FOXN4
|
mRNA
|
Humans
|
Hypermethylated (2.4% normal vs 4.3% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
269
|
Methylation Status of GALR2
|
mRNA
|
Humans
|
Hypermethylated (2% normal vs 4.3% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
270
|
Methylation Status of DPYS
|
mRNA
|
Humans
|
Hypermethylated (24.2% normal vs 42.71% in Cancerous condition)
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
271
|
Methylation Status of (DPYS or NKX2-5)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
272
|
Methylation Status of (CALSTN1 or DYPS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
273
|
Methylation Status of (NSE1 or DPYS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
274
|
Methylation Status of (NSE1 or SPOCK2)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
275
|
Methylation Status of (SLC16A12 or DPYS)
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
prostate cancer Vs normal prostate
|
p<0.05
|
Tissue
|
18446232
|
|
378
|
Methylation Status of RASSF1
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
|
380
|
Serum PSA + DRE + Methylation Status of RARB
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p<0.06
|
Expressed Prostatic Secretion
|
18948370
|
|
381
|
Serum PSA + DRE + Methylation Status of (GSTP1, APC, RARB, and RASSF1)
|
mRNA
|
Humans
|
GSTP1, APC, RARB, and RASSF1 Hypermethylated in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p<0.01
|
Expressed Prostatic Secretion
|
18948370
|
|
382
|
Serum PSA + DRE + Methylation Status of RASSF1
|
mRNA
|
Humans
|
RASSF1 Hypermethylated in Prostate Cancer
|
Diagnostic
|
Benign vs. PCA
|
p< 0.05
|
Expressed Prostatic Secretion
|
18948370
|
|
386
|
Serum PSA + DRE + Methylation Status of GSTP1
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
|
387
|
Serum PSA + DRE + Methylation Status of APC
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.01
|
Expressed Prostatic Secretion
|
18948370
|
|
388
|
Serum PSA + DRE + Methylation Status of RARB
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.01
|
Expressed Prostatic Secretion
|
18948370
|
|
389
|
Serum PSA + DRE + Methylation Status of RASSF1
|
mRNA
|
Humans
|
Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
|
390
|
Serum PSA + DRE + Methylation Status of (GSTP1, APC, RARB, and RASSF1)
|
mRNA
|
Humans
|
GSTP1, APC, RARB, and RASSF1 Hypermethylated in Prostate Cancer
|
Diagnostic
|
(Benign Samples + Gleason sums < 7) Vs ≥ 7
|
p<0.05
|
Expressed Prostatic Secretion
|
18948370
|
|
410
|
Methylation Status of RARB2
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCa stage I-III VS PCa Stage IV
|
p=0.027
|
Serum
|
19131636
|
|
411
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCA stage I-III VS PCA Stage IV
|
p=0.019
|
Serum
|
19131636
|
|
412
|
Methylation Status of GSTP1+RARB2
|
Methylation
|
Humans
|
Methylated in Stage IV PCa
|
Prognostic
|
PCA stage I-III VS PCA Stage IV
|
p=0.019
|
Serum
|
19131636
|
|
438
|
Methylation Status of: Chromosome 20 open reading frame 103 (C20orf103); Homeobox D9 (HOXD9); Nuclear receptor subfamily, group A, member 2 (NR5A2); Distal-less homeobox 5 (DLX5); Iroquois homeobox 1 (IRX1); Spastic paraplegia 20 (SPG20); Transcription factor AP-2 alpha (TFAP2A); Wilms tumor 1 (WT1); SIX homeobox 6 (SIX6); Homeobox D4 (HOXD4) ; Transcription factor 7-like 1 (TCF7L1); Sonic hedgehog homolog (SHH); Protocadherin, gamma subfamily C,5 (PCDHG5); Methionine aminopeptidase 1D (MAP1D); Runt-related transcription factor 1 (RUNX1)
|
Methylation
|
Humans
|
Hypermethylated in PCa: [Chromosome 20 open reading frame 103 (C20orf103) (3.7 fold); Homeobox D9 (HOXD9) (3.2 fold); Nuclear receptor subfamily, group A, member 2 (NR5A2) (3.1 fold); Distal-less homeobox 5 (DLX5) (3.7 fold); Iroquois homeobox 1 (IRX1) (3.0 fold); Spastic paraplegia 20 (SPG20) (3.0 fold); Transcription factor AP-2 alpha (TFAP2A) (2.9 fold); Wilms tumor 1 (WT1) (2.9 fold); SIX homeobox 6 (SIX6) (2.8 fold); Homeobox D4 (HOXD4) (2.7 fold) ; Transcription factor 7-like 1 (TCF7L1) (2.6 fold); Sonic hedgehog homolog (SHH) (2.5 fold) ; Protocadherin , gamma subfamily C,5 (PCDHG5) (2.4 fold); Methionine aminopeptidase 1D (MAP1D) (2.3 fold); Runt-related transcription factor 1 (RUNX1) (2.3 fold);]
|
Diagnostic
|
Cancer Vs Non Cancer
|
p<0.05
|
Tissue
|
19283074
|
|
439
|
Methylation Status of: Ventral anterior homeobox 1 (VAX1); Homeobox D3 (HOXD3); CAP-GLY domain containing linker protein family (CLIP4); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) ; Glycoprotein V (GP5); Somatostatin receptor 1 (SSTR1); Methylthioadenosine phosporylase (MTAP); NK2 homeobox 2 (NKX2-2); Homeobox C11 (HOXC11); Ladybird homeobox 1 (LBX1); Motor neuron and pancreas homeobox 1 (MNX1); Glutamate receptor, metabotropic 1 (GRM1); LIM homeobox 9 (LHX9); Microtubule-associated protein tau (MAPT); Galactosidase, beta 1-like (GLB1L)
|
Methylation
|
Humans
|
Hypermethylated in Progression (PP4): [Ventral anterior homeobox 1 (VAX1) (2.7 fold); Homeobox D3 (HOXD3) (2.3 fold); CAP-GLY domain containing linker protein family (CLIP4) (2.1 fold); Calcium channel, voltage dependent, T-type, alpha 1G 2.0 subunit (CACNA1G) (2.0 fold); Glycoprotein V (GP5) (1.9 fold); Somatostatin receptor 1 (SSTR1) (1.8 fold); Methylthioadenosine phosporylase (MTAP) (1.8 fold); NK2 homeobox 2 (NKX2-2) (1.7 fold); Homeobox C11 (HOXC11) (1.6 fold); Ladybird homeobox 1 (LBX1) (1.6 fold); Motor neuron and pancreas homeobox 1 (MNX1) (1.6 fold); Glutamate receptor, metabotropic 1 (GRM1) (1.6 fold); LIM homeobox 9 (LHX9) (1.6 fold); Microtubule-associated protein tau (MAPT) (1.5 fold); Galactosidase, beta 1-like (GLB1L) (1.5 fold)]
|
Prognostic
|
Gleason Score 6 (Pure pattern 3) vs Gleason Score 8 (Pure Pattern 4)
|
p<0.05
|
Tissue
|
19283074
|
|
485
|
Methylation Status of GSTP1 or RASSF1A
|
Methylation
|
Humans
|
HyperMethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Tumor
|
p<0.05
|
Urine
|
20632177
|
|
580
|
Methylation Status of [A4GALT; ADAM8; ALOX15B; BIK; CCK; CRCP; CTSC; CXCL2; CXCL3; CYBA; EIF4B; GSTM1 ; GSTM2; IGF2; LTF; MCAM; PDCD1; PDPN; PKMYT1; PPP1R3C; RAB32; RFTN1; SERPINB1; SLC16A5; SOCS1; TIMP3; TNF]
|
Methylation
|
Humans
|
HyperMethylated in PCa ( Positive Fold change): [A4GALT(2.0 fold) ; ADAM8(3.9 fold); ALOX15B(5.1fold, 2.7 fold); BIK(2.6 fold); CCK(9.3 fold); CRCP(2.1fold); CTSC(3.7 fold); CXCL2(3.2 fold); CXCL3(3.0fold); CYBA(3.8 fold); EIF4B(3.5 fold); GSTM1 (20.5 fold); GSTM2(4.1 fold); IGF2(4.2 fold); LTF(2.1 fold); MCAM(2.7 fold); PDCD1(3.2 fold); PDPN(4.5 fold); PKMYT1(2.9 fold); PPP1R3C(8.2 fold) ; RAB32(3.3 fold); RFTN1(5.5 fold); SERPINB1(2.4 fold); SLC16A5(17.2fold, 4.2 fold); SOCS1(2.6 fold); TIMP3(2.2 fold); TNF(2.0 fold)]
|
Diagnostic
|
Tumor Vs Tumor Adjacent
|
p=0.013
|
Tissue
|
21237555
|
|
581
|
Methylation Status of [ALDH1A3; NR4A2; PF4; RELB; SOCS1; TNFRSF1B; ZBTB11; ZNF365]
|
Methylation
|
Humans
|
HypoMethylated in PCa: ( Negative Fold change): [ALDH1A3(2.6 fold); NR4A2(2.5 fold); PF4(3.4 fold); RELB(2.1 fold); SOCS1(8.2 fold); TNFRSF1B(3.0 fold); ZBTB11(2.9 fold); ZNF365(5.0 fold)]
|
Diagnostic
|
Tumor Vs Tumor Adjacent
|
p=0.013
|
Tissue
|
21237555
|
|
702
|
Methylation Status of (RARB or GSTP1 or RASSF1)
|
Methylation
|
Humans
|
Hypermethylated in Cancer
|
Prognostic
|
Methylation in Patients with PCa
|
NA
|
Urine
|
21822036
|
|
703
|
Methylation Status of RARB
|
Methylation
|
Humans
|
Hypermethylated in Cancer
|
Prognostic
|
Methylation in Patients with PCa
|
NA
|
Tissue
|
21822036
|
|
704
|
Methylation Status of RARB
|
Methylation
|
Humans
|
Hypermethylated in Gleason Score 7 (PMR>=50)
|
Prognostic
|
Gleason Score 6 Vs Gleason Score 7
|
p=0.01
|
Urine
|
21822036
|
|
721
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
|
722
|
Methylation Status of RAR-2β
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
|
723
|
Methylation Status of GST-Pi
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
negative histology followed by a positive biopsy less than 24 months later
|
NA
|
Tissue
|
19755651
|
|
804
|
Methylation of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
NA
|
Tissue
|
22077694
|
|
805
|
Methylation of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
P=0.012
|
Tissue
|
22077694
|
|
806
|
Methylation of GSTP1 + APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
negative histology followed by a positive biopsy more than 24 months later
|
NA
|
Tissue
|
22077694
|
|
821
|
Methylation Status of AIM1
|
Methylation
|
Humans
|
Decreased hypermethylation in progression
|
Prognostic
|
Time To Progression
|
Univariate: p = 0.02 ; Multivariate: p = 0.05
|
Tissue
|
22127895
|
|
889
|
Methylation Status of TBX15
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p<0.01
|
Tissue
|
22452941
|
|
890
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p<0.01
|
Tissue
|
22452941
|
|
891
|
Methylation Status of CYP26A1
|
Methylation
|
Humans
|
Highly methylated in ERG positive fusion compared to ERG negative fusion
|
Prognostic
|
ERG positive fusion compared to ERG negative fusion in Prostate cancer
|
p≤0.041
|
Tissue
|
22452941
|
|
892
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Pathological Stage (pT2 Vs pT3/pT4)
|
p=0.026
|
Tissue
|
22452941
|
|
893
|
Methylation Status of TBX15
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Pathological Stage (pT2 Vs pT3/pT4)
|
p=0.010
|
Tissue
|
22452941
|
|
894
|
Methylation Status of HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Gleason score as ≤ 7 Vs 8 and above
|
p<0.001
|
Tissue
|
22452941
|
|
895
|
Methylation Status of TBX15 or HOXD3
|
Methylation
|
Humans
|
Differentially Expressed
|
Prognostic
|
Disease specific survival Vs no survival
|
p=0.044
|
Tissue
|
22452941
|
|
921
|
Methylation Status Of A0X1; CYBA; EDG3; ELF4; EPB41L3; FLJ12056; FLJ90650; FLT4; GAS6; GRASP; GSTP1; HAAO; HIF3A; HOXC11; LEP; MGC39606; MOBKL2B; RAB34; RARb; RHCG; RND2; SLC34A2; SPATA6; TPM4; ZNF154
|
Methylation
|
Humans
|
Methylated in PCA:
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p<0.0001
|
Tissue
|
22589488
|
|
922
|
Methylation Status Of ACTL6B; AEBP1; AMID; CD8A; CRIP1; FLJ30934; FLNC; FMOD; FOXE3; GAS7; GDPD5; HS3ST2; LOC349136; NEUROG1; PLTP; PTGER2; RASGRF2; RUNX3; SIX6; SLC9A3; SPSB4; SRD5A2; SUSD3; SYT10; TMEM74
|
Methylation
|
Humans
|
Hypermethlated in recurrent prostate cancer :
|
Prognostic
|
recurrent prostate cancer Vs nonrecurrent cancer
|
NA
|
Tissue
|
22589488
|
|
923
|
Methylation Status Of CHST7; LMX1B; RAFTLIN; RASGRF2; TNFRSF10D; ZNF135
|
Methylation
|
Humans
|
Methylated with Clinical Recurrence
|
Prognostic
|
clinical recurrence Vs biochemical recurrence
|
NA
|
Tissue
|
22589488
|
|
924
|
Methylation Status Of ALPL; AMPH; BCDIN3; BCL11B; BRD4; C18orf34; DCAMKL1; FGF5; FLJ42486; JAM2; LHX9; LOC283537; LRAT; PDE4B; POU3F3; PTGS2; RASGRF2; SLC27A6; SLC03A1; SPSB4; STAT3; SYN2; TACR3; TIRAP; WNT11
|
Methylation
|
Humans
|
Methylated with Systemic Recurrence
|
Prognostic
|
systemic recurrence Vs local recurrence
|
NA
|
Tissue
|
22589488
|
|
925
|
Methylation Status Of HIF3A; HAAO; RARb; GSTP1
|
Methylation
|
Humans
|
Methylated with Systemic Recurrence
|
Diagnostic
|
Tumor Vs Normal Tissues
|
p<0.0182
|
Tissue
|
22589488
|
|
926
|
Methylation Status Of CRIP1; RUNX3; HS3ST2; FLNC; RASGRF2
|
Methylation
|
Humans
|
Methylated in PCA:
|
Prognostic
|
recurrent prostate cancer Vs nonrecurrent cancer
|
NA
|
Tissue
|
22589488
|
|
927
|
Methylation Status Of PHLDA3; RASGRF2; TNFRSF10D; ZNF135
|
Methylation
|
Humans
|
Hypermethlated in recurrent prostate cancer :
|
Prognostic
|
clinical recurrence Vs biochemical recurrence
|
NA
|
Tissue
|
22589488
|
|
928
|
Methylation Status Of BCL11B; POU3F3; RASGRF2
|
Methylation
|
Humans
|
Methylated with Clinical Recurrence
|
Prognostic
|
systemic recurrence Vs local recurrence
|
NA
|
Tissue
|
22589488
|
|
1015
|
NA
|
Methylation
|
Humans
|
Hypermethylation in PCa (Δ Log Intensity): []; Hypomethylated in PCa: (Δ Log intensity): []
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
NA
|
Tissue
|
23119026
|
|
1016
|
Aldehyde Oxidase 1 (AOX1)
|
Methylation
|
Humans
|
Hypermethylation in PCa
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
p = 7.46 x10^-8
|
Tissue
|
23119026
|
|
1017
|
Spondin 2 (SPON2)
|
Methylation
|
Humans
|
Hypermethylation in PCa
|
Diagnostic
|
Pca Tumor Vs Tumor Adjacent
|
p = 2.1 x10^-14
|
Tissue
|
23119026
|
|
1038
|
Alanyl membrane aminopeptidase (ANPEP)
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant Tissue
|
p=0.0023
|
Tissue
|
23322201
|
|
1039
|
Alanyl membrane aminopeptidase (ANPEP)
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant Tissue
|
p=0.0025
|
Tissue
|
23322201
|
|
1073
|
Methylation Status of RASSF1A
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23431474
|
|
1074
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
p<0.001
|
Tissue
|
23431474
|
|
1075
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in early stages of PCa
|
Prognostic
|
Stage 1 & 2 Vs Stage 3 & 4
|
p<0.049
|
Tissue
|
23431474
|
|
1179
|
Methylation Status of BNC1
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0476
|
Tissue
|
23896626
|
|
1180
|
Methylation Status of FZD1
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0363
|
Tissue
|
23896626
|
|
1181
|
Methylation Status of SYN2
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.049
|
Tissue
|
23896626
|
|
1182
|
Methylation Status of ZNF783
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.011
|
Tissue
|
23896626
|
|
1183
|
Methylation Status of CYB5R2
|
Methylation
|
Humans
|
Hypermethylated in PCa (β atleast ≥ 0.2)
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p =0.0003
|
Tissue
|
23896626
|
|
1185
|
Methylation Status of AOX1 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1186
|
Methylation Status of AOX1 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1187
|
Methylation Status of C1orf114 (as continous variable)
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1188
|
Methylation Status of C1orf114 (High vs. Low)
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1189
|
Methylation Status of GAS6 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1190
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1191
|
Methylation Status of HAPLN3 (as continous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1192
|
Methylation Status of HAPLN3 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1193
|
Methylation Status of KLF8 (High vs. Low)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1194
|
Methylation Status of KLF8 (as continuous variable)
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1195
|
Methylation Status of MOB3B
|
Methylation
|
Humans
|
Hypermethylated in Prostate Cancer
|
Prognostic
|
Biochemical recurrence
|
P < 0.001
|
Tissue
|
23918943
|
|
1196
|
Methylation Status of AOX1/C1orf114/HAPLN3
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
NA
|
Tissue
|
23918943
|
|
1197
|
Methylation Status of AOX1/C1orf114/HAPLN3
|
Methylation
|
Humans
|
Lower Methylation in Patients with Longer Survival
|
Prognostic
|
Biochemical recurrence
|
NA
|
Tissue
|
23918943
|
|
1213
|
Methylation Status of HIST1H4K
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
p<0.0001
|
Urine
|
24065480
|
|
1218
|
Methylation Status of APC
|
Methylation
|
Humans
|
Hypermethylated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Tissue
|
24086370
|
|
1219
|
Methylation Status of GSTP1
|
Methylation
|
Humans
|
Hypermethylated in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Serum
|
24086370
|
|
1398
|
Methylation status of GABRE + miR-224 +miR-452
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Non Malignant
|
p=0.001
|
Tissue
|
24737792
|
|
1399
|
Methylation status of GABRE + miR-224 +miR-452 (as continous value )
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008
|
Tissue
|
24737792
|
|
1400
|
Methylation status of GABRE + miR-224 +miR-452 (High vs. Low )
|
miRNA + Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Cohort 1: Univariate: p<0.001; Multivariate: p= 0.019 Cohort 2: Univariate: p<0.001; Multivariate: p=0.008
|
Tissue
|
24737792
|
|
1444
|
Methylation status of genes (GSTM2; GSTP1; RARB; ALOX12; APC; PDGFRB; SCGB3A1; CFTR; MT1A; PENK; TERT; CCNA1; RARA; TAL1; ERG; MET; GFI1; MYCL2; SEPT9; COL18A1; KLK10; MFAP4; MMP14; TBX1; EYA4; NEU1; POMC; GADD45A; HTR1B; RASSF1; CDH13; PDGFRA; IRAK3; ASCL2; ESR1; HFE; IGFBP7; RARRES1; CAV1; THY1; BMP4;)
|
Methylation
|
Humans
|
Hypermethylated in Pca
|
Diagnostic
|
Prostate Cancer Vs Normal Prostate
|
NA
|
Tissue
|
24961912
|
|
1599
|
Methylation Status of IL-6
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.03
|
Blood
|
26265203
|
|
1600
|
Methylation Status of ICAM-1
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.02
|
Blood
|
26265203
|
|
1601
|
Methylation Status of IFN
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.02
|
Blood
|
26265203
|
|
1724
|
CRIP3
|
Methylation
|
Humans
|
Upregulated in PCa
|
Prognostic
|
Reclassification (Progression Vs No Progression)
|
p=0.017
|
Urine
|
30777394
|
|
1733
|
Methylation Status of cg12799885
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: EMX2OS: (-5.98142); LINC02137 (-5.28623); LINC01116 (-3.59594); LINC00839: (- 4.30616); AL161645.1: (-4.9543); AC012123.1: (-4.63826); AL354793.1 (-5.45876); LINC02385: (-5.3465); HOXBâ€AS3 (-5.22943); AC005674.1: (-3.98991);]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
|
1734
|
Methylation Status of DOCK2
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: hsaâ€mirâ€891a (-4.8); hsaâ€mirâ€892a (-5.14); hsaâ€mirâ€1224 (-3.66); hsaâ€mirâ€93 (1.79); hsaâ€mirâ€23c (-2.96); hsaâ€mirâ€1251 (-2.76); hsaâ€mirâ€204 (-1.84); hsaâ€mirâ€323b (-2.31); hsaâ€mirâ€200c (1.58); hsaâ€mirâ€96 (1.98);]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
|
1735
|
Methylation Status of FBXO30
|
Methylation
|
Humans
|
Differentially Expressed [Log Fold Change: SERPINA5: (-6.78954); MFSD2A (− 5.97025); ACSL6: (− 4.99597); MCF2: (−5.26855); EMX2: (− 6.79059); HOXB8: (− 6.24965); CLDN2: (−7.91887); AKR1B1: (− 3.87736); SPINK2: (−7.41992); CYP19A1: (−5.40444;]
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
|
1736
|
Methylation Status of GRASP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
|
1737
|
Methylation Status of HIF3A
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
|
1738
|
Methylation Status of MOB3B
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
|
1739
|
Methylation Status of PFKP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
|
1740
|
Methylation Status of TPM4
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p < 0.001
|
Tissue
|
30866497
|
|
1741
|
Methylation Status of cg12799885
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.025
|
Tissue
|
30866497
|
|
1742
|
Methylation Status of DOCK2
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p < 0.001; Multivariate: p=0.004
|
Tissue
|
30866497
|
|
1743
|
Methylation Status of GRASP
|
Methylation
|
Humans
|
Hypermethylated in PCa
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p < 0.001; Multivariate: p=0.037
|
Tissue
|
30866497
|
|
1744
|
Methylation Status of HIF3A
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.005 Multivariate: p =0.027
|
Tissue
|
30866497
|
|
1745
|
Methylation Status of PFKP
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.001 Multivariate: p=0.028
|
Tissue
|
30866497
|
|
1746
|
Methylation Status of TPM4
|
Methylation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: p=0.038;
|
Tissue
|
30866497
|
|
1813
|
APC; HOXD3; TGFβ2; GSTP1; KLK10
|
Methylation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs Benign
|
p<0.05
|
Urine
|
30470249
|
|
1814
|
APC
|
Methylation
|
Humans
|
NA
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.01
|
Urine
|
30470249
|
|
1815
|
HOXD3
|
Methylation
|
Humans
|
NA
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.01
|
Urine
|
30470249
|
|
1816
|
TGFβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.05
|
Urine
|
30470249
|
|
1817
|
GSTP1
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.01
|
Urine
|
30470249
|
|
1818
|
KLK10
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.001
|
Urine
|
30470249
|
|
1819
|
TBX15
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.05
|
Urine
|
30470249
|
|
1820
|
HOXD3+GSTP1
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Benign Vs High CAPRA Score
|
p<0.001
|
Urine
|
30470249
|
|
1860
|
Promoter methylation of: miR-193b+ miR-34b/c
|
Methylation
|
Humans
|
Upregulated in Recurrent PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
30373654
|
|
1861
|
Methlyation Status of APC, GSTP1 RARβ2
|
Methylation
|
Humans
|
Upregulated in PCa (Non PCa: 1504.7 Vs PCa: 1657.1)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Tissue
|
30373654
|
|
1862
|
Promoter methylation of: miR-193b+ miR-34b/c
|
Methylation
|
Humans
|
Upregulated in PCa (Non PCa: 1504.7 Vs PCa: 1657.1)
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Urine
|
30373654
|
|
1863
|
Methlyation Status of APC, GSTP1 RARβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Urine
|
30373654
|
|
1864
|
Methlyation Status of APC, GSTP1 RARβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Diagnostic
|
Prostate Cancer Vs Controls
|
p<0.05
|
Urine
|
30373654
|
|
1865
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
|
1866
|
Methlyation Status of GSTP1
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
|
1867
|
Methlyation Status of RARβ2
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
|
1868
|
Methlyation Status of miR-34b/c
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Gleason Grade 1 Vs Gleason Grade 2-5
|
p<0.01
|
Tissue
|
30373654
|
|
1869
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Low & Intermediate Risk Vs High Risk
|
p<0.01
|
Tissue
|
30373654
|
|
1870
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Low & Intermediate Risk Vs High Risk
|
p<0.05
|
Tissue
|
30373654
|
|
1871
|
Promoter methylation of: miR-193b+ miR-34b/c
|
Methylation
|
Humans
|
Methylated in Gleason Grade 2-5
|
Prognostic
|
Prostate Cancer Specific Survival Vs No Survival
|
p=0.017
|
Tissue
|
30373654
|
|
1872
|
Methlyation Status of APC
|
Methylation
|
Humans
|
Methylated in High Risk
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.044
|
Tissue
|
30373654
|
|
1873
|
Promoter methylation of: GSTP1
|
Methylation
|
Humans
|
Methylated in High Risk
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Tissue
|
30373654
|
|
1874
|
Methlyation Status of miR-34b/c
|
Methylation
|
Humans
|
Methylated in PCa
|
Prognostic
|
Biochemical Recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Tissue
|
30373654
|
|
1943
|
Methylation status of A0X1
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1944
|
Methylation status of CYBA
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1945
|
Methylation status of EDG3
|
Methylation
|
Humans
|
Upregulated in PCa [mean PC/mean]: (2.34 fold)
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1946
|
Methylation status of ELF4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1947
|
Methylation status of EPB41L3
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1948
|
Methylation status of FLJ12056
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1949
|
Methylation status of FLJ90650
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1950
|
Methylation status of FLT4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1951
|
Methylation status of GAS6
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1952
|
Methylation status of GRASP
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1953
|
Methylation status of GSTP1
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1954
|
Methylation status of HAAO
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1955
|
Methylation status of HIF3A
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1956
|
Methylation status of HOXC11
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1957
|
Methylation status of LEP
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1958
|
Methylation status of MGC39606
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1959
|
Methylation status of MOBKL2B
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1960
|
Methylation status of RAB34
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1961
|
Methylation status of RARb
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1962
|
Methylation status of RHCG
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1963
|
Methylation status of RND2
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1964
|
Methylation status of SLC34A2
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1965
|
Methylation status of SPATA6
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1966
|
Methylation status of TPM4
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1967
|
Methylation status of ZNF154
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Diagnostic
|
Tumor Vs Normal Tissues
|
<0.0001
|
Tissue
|
22589488
|
|
1968
|
Methylation status of ACTL6B
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1969
|
Methylation status of AEBP1
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0021
|
Tissue
|
22589488
|
|
1970
|
Methylation status of AMID
|
Methylation
|
Humans
|
Differentially Methylated between PCa and Normal
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1971
|
Methylation status of CD8A
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1972
|
Methylation status of CRIP1
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0037
|
Tissue
|
22589488
|
|
1973
|
Methylation status of FLJ30934
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1974
|
Methylation status of FLNC
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1975
|
Methylation status of FMOD
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1976
|
Methylation status of FOXE3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1977
|
Methylation status of GAS7
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1978
|
Methylation status of GDPD5
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1979
|
Methylation status of HS3ST2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1980
|
Methylation status of LOC349136
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1981
|
Methylation status of NEUROG1
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1982
|
Methylation status of PLTP
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1983
|
Methylation status of PTGER2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1984
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1985
|
Methylation status of RUNX3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1986
|
Methylation status of SIX6
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1987
|
Methylation status of SLC9A3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1988
|
Methylation status of SPSB4
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0008
|
Tissue
|
22589488
|
|
1989
|
Methylation status of SRD5A2
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1990
|
Methylation status of SUSD3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0014
|
Tissue
|
22589488
|
|
1991
|
Methylation status of SYT10
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0001
|
Tissue
|
22589488
|
|
1992
|
Methylation status of TMEM74
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Recurrent prostate cancer Vs nonrecurrent cancer
|
<0.0005
|
Tissue
|
22589488
|
|
1993
|
Methylation status of CHST7
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0050
|
Tissue
|
22589488
|
|
1994
|
Methylation status of LMX1B
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0021
|
Tissue
|
22589488
|
|
1995
|
Methylation status of PHLDA 3
|
Methylation
|
Humans
|
Hypermethlated in Recurrent prostate cancer
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0772
|
Tissue
|
22589488
|
|
1996
|
Methylation status of RAFTLIN
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0050
|
Tissue
|
22589488
|
|
1997
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0015
|
Tissue
|
22589488
|
|
1998
|
Methylation status of TNFRSF10D
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0008
|
Tissue
|
22589488
|
|
1999
|
Methylation status of ZNF135
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Clinical recurrence vs. biochemical recurrence
|
<0.0061
|
Tissue
|
22589488
|
|
2000
|
Methylation status of ALPL
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0182
|
Tissue
|
22589488
|
|
2001
|
Methylation status of AMPH
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0021
|
Tissue
|
22589488
|
|
2002
|
Methylation status of BCDIN3
|
Methylation
|
Humans
|
Differentially Methylated in Clinical recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2003
|
Methylation status of BCL11B
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2004
|
Methylation status of BRD4
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0038
|
Tissue
|
22589488
|
|
2005
|
Methylation status of C18orf34
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2006
|
Methylation status of DCAMKL1
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2007
|
Methylation status of FGF5
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2008
|
Methylation status of FLJ42486
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2009
|
Methylation status of JAM2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2010
|
Methylation status of LHX9
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2011
|
Methylation status of LOC283537
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2012
|
Methylation status of LRAT
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0034
|
Tissue
|
22589488
|
|
2013
|
Methylation status of PDE4B
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2014
|
Methylation status of POU3F3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2015
|
Methylation status of PTGS2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0153
|
Tissue
|
22589488
|
|
2016
|
Methylation status of RASGRF2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0002
|
Tissue
|
22589488
|
|
2017
|
Methylation status of SLC27A6
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0017
|
Tissue
|
22589488
|
|
2018
|
Methylation status of SLC03A1
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2019
|
Methylation status of SPSB4
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2020
|
Methylation status of STAT3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0017
|
Tissue
|
22589488
|
|
2021
|
Methylation status of SYN2
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0001
|
Tissue
|
22589488
|
|
2022
|
Methylation status of TACR3
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0086
|
Tissue
|
22589488
|
|
2023
|
Methylation status of TIRAP
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0003
|
Tissue
|
22589488
|
|
2024
|
Methylation status of WNT11
|
Methylation
|
Humans
|
Methylated in systemic Recurrence
|
Prognostic
|
Systemic recurrence vs. local recurrence
|
<0.0011
|
Tissue
|
22589488
|